INITIAL PSA SERUM LEVEL AND ITS RELATION TO PROSTATE
CANCER PROGRESSION IN MEN TREATED HORMONALLY
Article published in Urologia Polska 2000/53/3.
authors
-
Romuald Zdrojowy, Jerzy Lorenz, Janusz Dembowski, Anna Kołodziej
- Katedra i Klinika Urologii Akademii Medycznej we Wrocławiu
Kierownik Kliniki: prof. dr hab. med. J. Lorenz
keywords
-
prostate cancer maximal androgen blockade PSA disease progression
summary
- Objectives. Androgen deprivation is the common treatment method of men
- with locally advanced prostate cancer. Nowadays there no data what kind of
- treatment - immediate or deferred - is more effective.
- Aim of the study. The aim was Comparing prostate cancer progression in
- men with locally advanced disease with relation to initial serum PSA level.
- So the relations between serum PSA level and biochemical progression
- fre±uency and time to any progression was to be examined.
- Material and methods. 112 men with locally advanced prostate cancer
- T3NxM0
- years. The men were treated by maximal androgen blockade. The main
- oncological effectiveness criterion was the presence or abscence of the disease
- progression. The prostate cancer progression was defined as biochemical,
- local or general progression. The biochemical progression fre±uency and time
- to biochemical, local and general progression were statistically analyzed.
- Results. During the time observation biochemical progression was observed
- in 99/112 (88.4%) patients; without were 13/112 (11.6%). The was no statistically
- significant difference between initial serum PSA level and the biochemical
- progression fre±uency (p > 0,05). There were also no correlation between serum
- PSA level and time to biochemical, local and general progression.
- Conclusion. There was no relation between biochemical progression
- frequency and no correlation with time to biochemical, local and general
- progression and initial serum PSA level in men with locally advanced prostate
- cancer treated by maximal androgen blockade.
references
- [1] Adolf sson, J., Carstensen, J., Lowhagen, T.: Deferred treatment in clinically
- localized prostatic carcinoma. Br. J. Urol. 1992, 69,183-188.
- [2] Adolf sson, J.: Deferred treatment of low grade stage T3 prostate cancer without
- distant metastases. J. Urol. 1993,149,326-329.
- [3] Altwein, J. E.: Therapeutic options in locally defined or advanced prostate cancer.
- Eur. Urol. 1999, 35, Suppl. 1, 9-12.
- [4] Anderson, J. B.: Early versus deferred hormone therapy. Eur. Urol. 1999, 36,
- Suppl. 2, 9-14.
- [5] Byar, D. P., Corle, D. K.: Hormone therapy for prostate cancer: results of the
- Veterans Administration Cooperative Urological Research Group Studies. NCI Mono-
- graph 1988, 7,165-170.
- [6] Fleshner, N. E., Trachtenberg, J.: Postepy i kontrowersje dotyczqce blokady
- androgenowej u chorych z zaawansowanym rakiem stercza. AUA Update Series
- 1998, 16, 74-79.
- [7] Huland, H., Graefen, M., Hammerer, P., Noldus, J., Haese, A., Fernan-
- dez, S., Huland, E.: Multivariate analysis ofpreoperative parameters for predic-
- tion of early PSA relapse after radical prostatectomy (RP). J. Urol. 1999,161, suppl.
- 4, 334.
- [8] Kleer, E., Oesterling, J. E.: PSA and staging of localized prostate cancer. Urol.
- Clin. N. Am. 1993, 20, 695-704.
- [9] Newling, D. W.: Treating clinically advanced, localized prostate cancer. Clin. Care
- Prostatic Disease 1996, 4,11-16.
- [10] Oesterling, J. E., Suman, V. J., Zincke, H., Bostwick, D. G.: PSA -detected
- (clinical stage Tlc or BJ prostate cancer: pathologically significant tumors. Urol.
- Clin. N. Am. 1993, 20, 687-693.
- [11] Partin, W., Pound, C. R., Eisenberger, M. A., Chan, D. W., Pearson, J. D.,
- Walsh, P. C: Prostate-specific antigen doubling time (PSADT), Gleason score and
- the time to PSA recurrence following radical prostatectomy predicts time to distant
- progression. J. Urol. 1999,161, Suppl. 4,175.
- [12] Schroder, F. H.: Leczenie hormonalne raka gruczolu krokowego - wspolczesne
- osiqgniecia i przyszlosc:. Czesc 1 maksymalna blokada androgenowa, leczenie wcz-
- esne versus, leczenie opoznione; dzialania niepozqdane. Eur. Urol. Update Series
- 1999, 1, 5-15.
- [13] Sherrill, L. A., Iocca, A. J., Blute, M. L., Bostwick, D. G., Zincke, H.:
- Clinical The prostate cancer treated by radical prostatectomy: outcome according to
- preoperative PSA and clinical grade in the PSA era. J. Urol. 1999,161, Suppl. 155.
- [14] The Medical Research Council Prostate Cancer Working Party Investi-
- gators Group: Immediate versus deferred treatment for advenced prostatic cancer:
- initial results of the Medical Research Cuncil Trial Br. J. Urol. 1997, 79, 235-246.
- [15] Zdrojowy, R.: Historia naturalna raka stercza. Choroby gruczołu krokowego. Wyd.
- Lek. PZWL, Warszawa 1997, 234-242.
|